(12) **Translation of European patent specification**

(11) **NO/EP 3543240 B1**

(19) NO

NORWAY

(51) Int Cl.

C07D 487/04 (2006.01) ***A61K 31/4985 (2006.01)*** ***C07D 307/80 (2006.01)***
A61K 31/343 (2006.01) ***A61K 31/519 (2006.01)*** ***C07D 471/04 (2006.01)***
A61K 31/429 (2006.01) ***A61P 19/06 (2006.01)*** ***C07D 513/04 (2006.01)***
A61K 31/437 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2022.09.19
(80)	Date of The European Patent Office Publication of the Granted Patent	2022.07.06
(86)	European Application Nr.	17872538.8
(86)	European Filing Date	2017.11.15
(87)	The European Application's Publication Date	2019.09.25
(30)	Priority	2016.11.16, CN, 201611008935 2017.11.13, CN, 201711115037
(84)	Designated Contracting States:	AL; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR
(73)	Proprietor	Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd., Suite 401, Building C31, Biomedical Industry Park 218 Xinghu Street, Suzhou Industrial Park China (Jiangsu) Pilot Free Trade Zone-Suzhou Area, Suzhou City, Jiangsu Province, 215123, Kina
(72)	Inventor	SHI, Dongfang, Building 18, 99 Jing 15 Road, Dingmao, Xinqu, Zhenjiang, Jiangsu 212009, Kina FU, Changjin, Building 18, 99 Jing 15 Road, Dingmao, Xinqu, Zhenjiang, Jiangsu 212009, Kina CHENG, Xi, Building 18, 99 Jing 15 Road, Dingmao, Xinqu, Zhenjiang, Jiangsu 212009, Kina ZHU, Jianghua, Building 18, 99 Jing 15 Road, Dingmao, Xinqu, Zhenjiang, Jiangsu 212009, Kina GU, Jie, Building 18, 99 Jing 15 Road, Dingmao, Xinqu, Zhenjiang, Jiangsu 212009, Kina
(74)	Agent or Attorney	BRYN AARFLOT AS, Stortingsgata 8, 0161 OSLO, Norge

(54) Title **URAT1 INHIBITOR AND USE THEREOF**

(56) References Cited:

WO-A1-2016/150255, WO-A1-03/009839, EP-A1-3 275 867, CN-A-108 727 267, CN-A-106 432 229, EP-A1-0 061 380, WO-A1-2016/108282, WO-A1-99/58519

MICHAEL F. WEMPE ET AL: "Developing Potent Human Uric Acid Transporter 1 (hURAT1) Inhibitors", JOURNAL OF MEDICINAL CHEMISTRY, vol. 54, no. 8, 28 April 2011 (2011-04-28) , pages 2701-2713, XP055109293, ISSN: 0022-2623, DOI: 10.1021/jm1015022

WALSH, THOMAS F.: "Synthesis of new imidazo[l, 2-b]pyridazine isosteres of potent imidazo[4, 5-b]pyridine angiotensin II antagonists", Bioorganic & Medicinal Chemistry Letters, vol. 4, no. 1, 31 December 1994 (1994-12-31), pages 219-222, XP055605445, ISSN: 0960-894X, DOI: 10.1016/S0960-894X(01)81150-1

LEE MING-HAN H ET AL: "A benefit-risk assessment of benzbromarone in the treatment of gout: was its withdrawal from the market in the best interest of patients?", DRUG SAFETY, ADIS PRESS, AUCKLAND, NZ, vol. 31, no. 8, 1 January 2008 (2008-01-01), pages 643-665, XP009141466, ISSN: 0114-5916

PATENTKRAV

1. Forbindelse eller et farmasøytisk akseptabelt salt derav, hvori forbindelsen er valgt fra forbindelsene vist ved følgende strukturer,


(II-A)


(II-B)


(II-C)


(II-D)


(III-A)


(IV-A)


(IV-B)


(IV-C)


(IV-D),

hvori

Y er karbonyl, svovel, sulfon, sulfoksid, eventuelt substituert metylen eller imino;

R^1 er hydrogen, deuterium, hydroksy, halogen, nitro, amino, cyano, C_{1-3} alkyl, substituert C_{1-3} alkyl, substituert C_{1-3} amino, C_{1-3} alkoksy eller substituert C_{1-3}-alkoksy;

R^2 er hydrogen, halogen, nitro, cyano, C_{1-3} alkyl eller C_{1-3} halogenalkyl;

R^3 er C_{1-4} alkyl, substituert C_{1-4} alkyl eller halogen;
m er et heltall fra 0 til 3;
n er 1 eller 2;
substituenten i gruppen Y er valgt fra gruppen bestående av hydroksyl, amino, cyano, karboksyl, C_{1-3} alkoksy eller C_{1-3} alkyl, substituenten i gruppen R^1, R^2 eller R^3 er valgt fra gruppen bestående av hydroksyl, halogen, nitro, amino eller cyano;
i formelen (II-D) og formelen (III-A) er Y ikke en karbonylgruppe;
forutsatt at forbindelsen ikke er 2-etylimidazo[1,2-a]pyrimidin-3-yl)-(4-hydroksyfenyl)metanon.

2. Forbindelse eller farmasøytisk akseptabelt salt derav ifølge krav 1, hvori Y er CH-OH, CH-NH_2, CH-CN, NH, NCH_3 eller CO-gruppe, og R^3 er en C_{2-3} alkyl; i formel (II-D) og formel (III-A) er Y ikke en karbonylgruppe.

3. Forbindelse eller farmasøytisk akseptabelt salt derav ifølge krav 1, hvori R^1 er hydrogen, deuterium, hydroksy, halogen, nitro, amino, cyano, C_{1-3} alkyl, C_{1-3} haloalkyl, C_{1-3}-alkoksy eller C_{1-3}-haloalkoksy, og m er 0, 1 eller 2.

4. Forbindelse eller farmasøytisk akseptabelt salt derav ifølge krav 1, hvori forbindelsen er valgt fra gruppen bestående av:
(3,5-dibrom-4-hydroksyfenyl)(2-etylimidazo[1,2-a]pyrimidin-3-yl)metanon;
(3,5-dibrom-4-hydroksyfenyl)(2-etylimidazo[2,1-b]tiozol-5-yl)metanon;
(3,5-dibrom-4-hydroksyfenyl)(2-etylimidazo[1,2-a]pyrazin-3-yl)metanon;
3-brom-5-[(2-etylimidazo[1,2-alpyridin-3-yl)hydroksymetyl]-2-hydroksy-benzonitril;
5-[(2-etylimidazo[1,2-a]pyridin-3-yl)hydroksymetyl]-2-hydroksybenzonitril;
2,6-dibrom-4-[(6-etylimidazo[2,1-b]tiozol-5-yl)hydroksymetyl]fenol;
2,6-dibrom-4-[(2-etylimidazo[1,2-a]pyrazin-3-yl)hydroksymetyl]fenol;
2-brom-4-[(2-etyl-6-fluorimidazo[1,2-a]pyridin-3-yl)hydroksymetyl]-6-fluor-fenol;
2,6-dibrom-4-[(2-etylpyrazolo[1,5-a]pyridin-3-yl)hydroksymetyl]fenol;
2,6-dibrom-4-[(6-brom-2-etylimidazo[1,2-a]pyridin-3-yl)hydroksymetyl]fenol;
2,6-dibrom-4-{[(2-etyl-7-(trifluormetyl)imidazo[1,2-a]pyridin-3-yl)]hydroksy-metyl}fenol;
2,6-dibrom-4-[(2-etylimidazo[1,2-a]pyridin-3-yl)metyl]fenol;

(3,5-dibrom-4-hydroksyfenyl)(6-etylimidazo[2,1-b][1,3,4]tiodiazol-5-yl)-metanon;
2-brom-4-(2-etylimidazo[1,2-a]pyridin-3-yl)hydroksymetyl-6-metylfenol;
2,6-dibrom-4-{(2-etyl-7-metoksyimidazo[1,2-a]pyridin-3-yl)hydroksy-metyl}fenol.

5. Farmasøytisk sammensetning omfattende forbindelsen ifølge hvilket som helst av kravene 1 til 4 eller farmasøytisk akseptabelt salt derav som aktiv ingrediens eller hovedaktiv ingrediens, og en farmasøytisk akseptabel bærer.

6. Forbindelse ifølge hvilket som helst av kravene 1 til 4 eller av et farmasøytisk akseptabelt salt derav for anvendelse for å fremme urinsyreutskillelse, spesielt for behandling eller forebygging av hyperurikemi eller gikt.